Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03381547 · ClinicalTrials.gov registry record · Phase 1
A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03381547 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 12 participants.
The verdict
NCT03381547, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
To evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants.
Interventions
- BIOLOGICAL Pegilodecakin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-12-18 |
| Est. Completion | 2018-02-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03381547
The ClinicalTrials.gov registry entry for NCT03381547 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegilodecakin is the first listed.
NCT03381547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03381547 about?
NCT03381547 is a clinical study titled "A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)". To evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants.
What is the current status of trial NCT03381547?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-12-18. Estimated completion is 2018-02-13.
What interventions are being tested in trial NCT03381547?
The interventions under investigation include: Pegilodecakin (BIOLOGICAL).
Who is sponsoring clinical trial NCT03381547?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.